Do Black Patients Need a Longer Course of Ledipasvir plus Sofosbuvir for HCV Infection?

An 8-week regimen of ledipasvir plus sofosbuvir (LDV/SOF) is approved for treatment of genotype 1 hepatitis C virus (HCV) infection in certain patients (treatment-naive, no cirrhosis, no human immunodeficiency virus infection, HCV RNA <6 million IU/mL). However, based on concern over lower treatment response among black patients and despite limited evidence, a guideline from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommends a 12-week regimen in black patients who are eligible for the 8-week regimen.

To investigate this issue further, in an observational study, researchers assessed sustained virologic response at 12 weeks after treatment ended (SVR12) in over 2600 HCV-infected p…